Natural killer cells in human autoimmune disorders

Arthritis Research and Therapy

Volumn 15, Issue 4, 2013, Pages

  Fogel, Leslie A ^a   Yokoyama, Wayne M ^b   French, Anthony R ^a  

^a WASHINGTON UNIVERSITY   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CYTOKINE; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; NATURAL KILLER CELL RECEPTOR;

ADAPTIVE IMMUNITY; AUTOIMMUNE DISEASE; AUTOIMMUNITY; B LYMPHOCYTE; CELL ACTIVATION; HEMOPHAGOCYTIC SYNDROME; HLA SYSTEM; HUMAN; IMMUNOREGULATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MULTIPLE SCLEROSIS; NATURAL KILLER CELL; REGULATORY MECHANISM; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; IMMUNOLOGY; LYMPHOCYTE ACTIVATION;

AUTOIMMUNE DISEASES; AUTOIMMUNITY; HUMANS; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION;

EID: 84880170685     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4232     Document Type: Review

References (145)

1. Progress in Autoimmune Diseases Research. , http://www.niaid.nih.gov/topics/autoimmune/documents/adccfinal.pdf
2. The Cost Burden of Autoimmune Disease: The Latest Front in the War on Healthcare Spending. , http://www.aarda.org/pdf/cbad.pdf
3. Yokoyama WM, Kim S, French AR. The dynamic life of natural killer cells. Annu Rev Immunol 2004, 22:405-429. 10.1146/annurev.immunol.22.012703.104711, 15032583.
4. Walzer T, Jaeger S, Chaix J, Vivier E. Natural killer cells: from CD3(-)NKp46(+) to post-genomics meta-analyses. Curr Opin Immunol 2007, 19:365-372. 10.1016/j.coi.2007.04.004, 17442558.
5. Shi F-D, Ljunggren HG, La Cava A, Van Kaer L. Organ-specific features of natural killer cells. Nat Rev Immunol 2011, 11:658-671. 10.1038/nri3065, 3620656, 21941294.
6. Hanna J, Goldman-Wohl D, Hamani Y, Avraham I, Greenfield C, Natanson-Yaron S, Prus D, Cohen-Daniel L, Arnon TI, Manaster I, Gazit R, Yutkin V, Benharroch D, Porgador A, Keshet E, Yagel S, Mandelboim O. Decidual NK cells regulate key developmental processes at the human fetal-maternal interface. Nat Med 2006, 12:1065-1074. 10.1038/nm1452, 16892062.
7. King A, Burrows T, Verma S, Hiby S, Loke YW. Human uterine lymphocytes. Hum Reprod Update 1998, 4:480-485. 10.1093/humupd/4.5.480, 10027599.
8. Cooper MA, Fehniger TA, Turner SC, Chen KS, Ghaheri BA, Ghayur T, Carson WE, Caligiuri MA. Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset. Blood 2001, 97:3146-3151. 10.1182/blood.V97.10.3146, 11342442.
9. Caligiuri MA. Human natural killer cells. Blood 2008, 112:461-469. 10.1182/blood-2007-09-077438, 2481557, 18650461.
10. Fehniger TA, Cooper MA, Nuovo GJ, Cella M, Facchetti F, Colonna M, Caligiuri MA. CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity. Blood 2003, 101:3052-3057. 10.1182/blood-2002-09-2876, 12480696.
11. Gumperz JE, Litwin V, Phillips JH, Lanier LL, Parham P. The Bw4 public epitope of HLA-B molecules confers reactivity with natural killer cell clones that express NKB1, a putative HLA receptor. J Exp Med 1995, 181:1133-1144. 10.1084/jem.181.3.1133, 2191933, 7532677.
12. Cella M, Longo A, Ferrara GB, Strominger JL, Colonna M. NK3-specific natural killer cells are selectively inhibited by Bw4-positive HLA alleles with isoleucine 80. J Exp Med 1994, 180:1235-1242. 10.1084/jem.180.4.1235, 2191670, 7931060.
13. Braud VM, Allen DSJ, O'Callaghan CA, Söderström K, D'Andrea A, Ogg GS, Lazetic S, Young NT, Bell JI, Phillips JH, Lanier LL, McMichael AJ. HLA-E binds to natural-killer-cell receptors CD94/NKG2A, B and C. Nature 1998, 391:795-799. 10.1038/35869, 9486650.
14. Borrego F, Ulbrecht M, Weiss EH, Coligan JE, Brooks AG. Recognition of human histocompatibility leukocyte antigen (HLA)-E complexed with HLA class I signal sequence-derived peptides by CD94/NKG2 confers protection from natural killer cell-mediated lysis. J Exp Med 1998, 187:813-818. 10.1084/jem.187.5.813, 2212178, 9480992.
15. Lee N, Llano M, Carretero M, Ishitani A, Navarro F, López-Botet M, Geraghty DE. HLA-E is a major ligand for the NK inhibitory receptor CD94/NKG2A. Proc Natl Acad Sci USA 1998, 95:5199-5204. 10.1073/pnas.95.9.5199, 20238, 9560253.
16. Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL, Spies T. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999, 285:727-729. 10.1126/science.285.5428.727, 10426993.
17. Mandelboim O, Lieberman N, Lev M, Paul L, Arnon TI, Bushkin Y, Davis DM, Strominger JL, Yewdell JW, Porgador A. Recognition of haemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells. Nature 2001, 409:1055-1060. 10.1038/35059110, 11234016.
18. Ljunggren HG, Karre K. In search of the 'missing self': MHC molecules and NK cell recognition. Immunol Today 1990, 11:237-244.
19. Kärre K, Ljunggren HG, Piontek G, Kiessling R. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 1986, 319:675-678. 10.1038/319675a0, 3951539.
20. Gasser S, Orsulic S, Brown EJ, Raulet DH. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 2005, 436:1186-1190. 10.1038/nature03884, 1352168, 15995699.
21. Stern-Ginossar N, Gur C, Biton M, Horwitz E, Elboim M, Stanietsky N, Mandelboim M, Mandelboim O. Human microRNAs regulate stress-induced immune responses mediated by the receptor NKG2D. Nat Immunol 2008, 9:1065-1073. 10.1038/ni.1642, 18677316.
22. Jonsson AH, Yokoyama WM. Natural killer cell tolerance licensing and other mechanisms. Adv Immunol 2009, 101:27-79.
23. Elliott JM, Yokoyama WM. Unifying concepts of MHC-dependent natural killer cell education. Trends Immunol 2011, 32:364-372. 10.1016/j.it.2011.06.001, 3151350, 21752715.
24. Zimmer J, Donato L, Hanau D, Cazenave JP, Tongio MM, Moretta A, de la Salle H. Activity and phenotype of natural killer cells in peptide transporter (TAP)-deficient patients (type I bare lymphocyte syndrome). J Exp Med 1998, 187:117-122. 10.1084/jem.187.1.117, 2199183, 9419217.
25. Anfossi N, Andre P, Guia S, Falk CS, Roetynck S, Stewart CA, Breso V, Frassati C, Reviron D, Middleton D, Romagné F, Ugolini S, Vivier E. Human NK cell education by inhibitory receptors for MHC class I. Immunity 2006, 25:331-342. 10.1016/j.immuni.2006.06.013, 16901727.
26. Fernandez NC, Treiner E, Vance RE, Jamieson AM, Lemieux S, Raulet DH. A subset of natural killer cells achieves self-tolerance without expressing inhibitory receptors specific for self-MHC molecules. Blood 2005, 105:4416-4423. 10.1182/blood-2004-08-3156, 1895026, 15728129.
27. Kim S, Poursine-Laurent J, Truscott SM, Lybarger L, Song YJ, Yang L, French AR, Sunwoo JB, Lemieux S, Hansen TH, Yokoyama WM. Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature 2005, 436:709-713. 10.1038/nature03847, 16079848.
28. Yokoyama WM, Kim S. Licensing of natural killer cells by self-major histocompatibility complex class I. Immunol Rev 2006, 214:143-154. 10.1111/j.1600-065X.2006.00458.x, 17100882.
29. Yokoyama WM, Kim S. How do natural killer cells find self to achieve tolerance?. Immunity 2006, 24:249-257. 10.1016/j.immuni.2006.03.006, 16546094.
30. Kim S, Sunwoo JB, Yang L, Choi T, Song YJ, French AR, Vlahiotis A, Piccirillo JF, Cella M, Colonna M, Mohanakumar T, Hsu KC, Dupont B, Yokoyama WM. HLA alleles determine differences in human natural killer cell responsiveness and potency. Proc Natl Acad Sci USA 2008, 105:3053-3058. 10.1073/pnas.0712229105, 2268583, 18287063.
31. Mailliard RB, Son Y-I, Redlinger R, Coates PT, Giermasz A, Morel PA, Storkus WJ, Kalinski P. Dendritic cells mediate NK cell help for Th1 and CTL responses: two-signal requirement for the induction of NK cell helper function. J Immunol 2003, 171:2366-2373.
32. Piccioli D, Sbrana S, Melandri E, Valiante NM. Contact-dependent stimulation and inhibition of dendritic cells by natural killer cells. J Exp Med 2002, 195:335-341. 10.1084/jem.20010934, 2193592, 11828008.
33. Mocikat R, Braumuller H, Gumy A, Egeter O, Ziegler H, Reusch U, Bubeck A, Louis J, Mailhammer R, Riethmuller G, Koszinowski U, Röcken M. Natural killer cells activated by MHC class I(low) targets prime dendritic cells to induce protective CD8 T cell responses. Immunity 2003, 19:561-569. 10.1016/S1074-7613(03)00264-4, 14563320.
34. Ferlazzo G, Tsang ML, Moretta L, Melioli G, Steinman RM, Münz C. Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells. J Exp Med 2002, 195:343-351. 10.1084/jem.20011149, 2193591, 11828009.
35. Pende D, Castriconi R, Romagnani P, Spaggiari GM, Marcenaro S, Dondero A, Lazzeri E, Lasagni L, Martini S, Rivera P, Capobianco A, Moretta L, Moretta A, Bottino C. Expression of the DNAM-1 ligands, Nectin-2 (CD112) and poliovirus receptor (CD155), on dendritic cells: relevance for natural killerdendritic cell interaction. Blood 2006, 107:2030-2036. 10.1182/blood-2005-07-2696, 16304049.
36. Nedvetzki S, Sowinski S, Eagle RA, Harris J, Vély F, Pende D, Trowsdale J, Vivier E, Gordon S, Davis DM. Reciprocal regulation of human natural killer cells and macrophages associated with distinct immune synapses. Blood 2007, 109:3776-3785. 10.1182/blood-2006-10-052977, 17218381.
37. Cerboni C, Zingoni A, Cippitelli M, Piccoli M, Frati L, Santoni A. Antigenactivated human T lymphocytes express cell-surface NKG2D ligands via an ATM/ATR-dependent mechanism and become susceptible to autologous NK-cell lysis. Blood 2007, 110:606-615. 10.1182/blood-2006-10-052720, 17405908.
38. Molinero LL, Domaica CI, Fuertes MB, Girart MV, Rossi LE, Zwirner NW. Intracellular expression of MICA in activated CD4 T lymphocytes and protection from NK cell-mediated MICA-dependent cytotoxicity. Hum Immunol 2006, 67:170-182. 10.1016/j.humimm.2006.02.010, 16698439.
39. Zingoni A, Palmieri G, Morrone S, Carretero M, Lopez-Botel M, Piccoli M, Frati L, Santoni A. CD69-triggered ERK activation and functions are negatively regulated by CD94/NKG2-A inhibitory receptor. Eur J Immunol 2000, 30:644-651. 10.1002/1521-4141(200002)30:2<644::AID-IMMU644>3.0.CO;2-H, 10671222.
40. De Maria A, Fogli M, Mazza S, Basso M, Picciotto A, Costa P, Congia S, Mingari MC, Moretta L. Increased natural cytotoxicity receptor expression and relevant IL-10 production in NK cells from chronically infected viremic HCV patients. Eur J Immunol 2007, 37:445-455. 10.1002/eji.200635989, 17273991.
41. Mehrotra PT, Donnelly RP, Wong S, Kanegane H, Geremew A, Mostowski HS, Furuke K, Siegel JP, Bloom ET. Production of IL-10 by human natural killer cells stimulated with IL-2 and/or IL-12. J Immunol 1998, 160:2637-2644.
42. Deniz G, Erten G, Kücüksezer UC, Kocacik D, Karagiannidis C, Aktas E, Akdis CA, Akdis M. Regulatory NK cells suppress antigen-specific T cell responses. J Immunol 2008, 180:850-857.
43. Martin-Fontecha A, Thomsen LL, Brett S, Gerard C, Lipp M, Lanzavecchia A, Sallusto F. Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming. Nat Immunol 2004, 5:1260-1265. 10.1038/ni1138, 15531883.
44. Morandi B, Bougra s G, Muller WA, Ferlazzo G, Munz C. NK cells of human secondary lymphoid tissues enhance T cell polarization via IFN-gamma secretion. Eur J Immunol 2006, 36:2394-2400. 10.1002/eji.200636290, 16917961.
45. Grossman WJ, Verb sky JW, Barchet W, Colonna M, Atkinson JP, Ley TJ. Human T regulatory cells can use the perforin pathway to cause autologous target cell death. Immunity 2004, 21:589-601. 10.1016/j.immuni.2004.09.002, 15485635.
46. Risma K, Jordan MB. Hemophagocytic lymphohistiocytosis: updates and evolving concepts. Curr Opin Pediatr 2012, 24:9-15. 10.1097/MOP.0b013e32834ec9c1, 22189397.
47. Côte M, Ménager MM, Burgess A, Mahlaoui N, Picard C, Schaffner C, Al-Manjomi F, Al-Harbi M, Alangari A, Le Deist F, Gennery AR, Prince N, Cariou A, Nitschke P, Blank U, El-Ghazali G, Ménasché G, Latour S, Fischer A, de Saint Basile G. Munc18-2 deficiency causes familial hemophagocytic lymphohistiocytosis type 5 and impairs cytotoxic granule exocytosis in patient NK cells. J Clin Invest 2009, 119:3765-3773. 10.1172/JCI40732, 2786810, 19884660.
48. Schleinitz N, Vély F, Harlé J-R, Vivier E. Natural killer cells in human autoimmune diseases. Immunology 2010, 131:451-458. 10.1111/j.1365-2567.2010.03360.x, 2999796, 21039469.
49. Grunebaum E, Malatzky-Goshen E, Shoenfeld Y. Natural killer cells and autoimmunity. Immunol Res 1989, 8:292-304. 10.1007/BF02935514, 2687403.
50. Baxter AG, Smyth MJ. The role of NK cells in autoimmune disease. Autoimmunity 2002, 35:1-14. 10.1080/08916930290005864, 11908701.
51. Flodstrom M, Shi FD, Sarvetnick N, Ljunggren HG. The natural killer cell-friend or foe in autoimmune disease?. Scand J Immunol 2002, 55:432-441. 10.1046/j.1365-3083.2002.01084.x, 11975754.
52. French AR, Yokoyama WM. N atural killer cells and autoimmunity. Arthritis Res Ther 2004, 6:8-14. 400423, 14979926.
53. Flodström-Tullberg M, Bryceson YT, Shi F-D, Höglund P, Ljunggren H-G. Natural killer cells in human autoimmunity. Curr Opin Immunol 2009, 21:634-640. 10.1016/j.coi.2009.09.012, 19892538.
54. Tian Z, Gershwin ME, Zhang C. Regulatory NK cells in autoimmune disease. J Autoimmun 2012, 39:206-215. 10.1016/j.jaut.2012.05.006, 22704425.
55. Park YW, Kee SJ, Cho YN, Lee EH, Lee HY, Kim EM, Shin MH, Park JJ, Kim TJ, Lee SS, Yoo DH, Kang HS. Impaired differentiation and cytotoxicity of natural killer cells in systemic lupus erythematosus. Arthritis Rheum 2009, 60:1753-1763. 10.1002/art.24556, 19479851.
56. Bossowski A, Urban M, Stasiak-Barmuta A. Analysis of circulating T gamma/ delta lymphocytes and CD16/56 cell populations in children and adolescents with Graves' disease. Pediatr Res 2003, 54:425-429. 10.1203/01.PDR.0000076663.94850.44, 12761360.
57. Ciampolillo A, Guastamacchia E, Amati L, Magrone T, Munno I, Jirillo E, Triggiani V, Fallacara R, Tafaro E. Modifications of the immune responsiveness in patients with autoimmune thyroiditis: evidence for a systemic immune alteration. Curr Pharm Des 2003, 9:1946-1950. 10.2174/1381612033454270, 12871179.
58. Cameron AL, Kirby B, Griffiths CEM. Circulating natu ral killer cells in psoriasis. Br J Dermatol 2003, 149:160-164. 10.1046/j.1365-2133.2003.05319.x, 12890211.
59. O'Gorman MR, Smith R, Garrison A, Shamiyeh E, Pachman L. Lymphocyte subsets in peripheral blood from newly diagnosed, untreated patients with juvenile dermatomyositis (JDM) are associated with disease activity scores (DAS). Arthritis Rheum 2002, 46:S490.
60. Wouters CH, Ceuppens JL, Stevens EA. Different circulating lymphocyte profiles in patients with different subtypes of juvenile idiopathic arthritis. Clin Exp Rheumatol 2002, 20:239-248.
61. Biron CA, Byron KS, Sullivan JL. Severe herpesvirus infections in an adolescent without natural killer cells. N Engl J Med 1989, 320:1731-1735. 10.1056/NEJM198906293202605, 2543925.
62. Jawahar S, Moody C, Chan M, Finberg R, Geha R, Chatila T. Natural Killer (NK) cell deficiency associated with an epitope-deficient Fc receptor type IIIA (CD16-II). Clin Exp Immunol 1996, 103:408-413. 2200361, 8608639.
63. Orange JS. Human natural killer cell deficiencies and susceptibility to infection. Microbes Infect 2002, 4:1545-1558. 10.1016/S1286-4579(02)00038-2, 12505527.
64. Dotta F, Censini S, van Halteren AGS, Marselli L, Masini M, Dionisi S, Mosca F, Boggi U, Muda AO, Del Prato S, Elliott JF, Covacci A, Rappuoli R, Roep BO, Marchetti P. Coxsackie B4 virus infection of beta cells and natural killer cell insulitis in recent-onset type 1 diabetic patients. Proc Natl Acad Sci USA 2007, 104:5115-5120. 10.1073/pnas.0700442104, 1829272, 17360338.
65. Ito T, Ito N, Saatoff M, Hashizume H, Fukamizu H, Nickoloff BJ, Takigawa M, Paus R. Maintenance of hair follicle immune privilege is linked to prevention of NK cell attack. J Invest Dermatol 2008, 128:1196-1206. 10.1038/sj.jid.5701183, 18160967.
66. Li CK, Varsani H, Holton JL, Gao B, Woo P, Wedderburn LR. Juvenile Dermatomyositis Research Group (UK and Ireland) MHC class I overexpression on muscles in early juvenile dermatomyositis. J Rheumatol 2004, 31:605-609. Juvenile Dermatomyositis Research Group (UK and Ireland).
67. Pachman L, O'Gorman MR, Lawton T, Liotta M, Pope RM, Greene M, Wu TT. Studies of muscle biopsies from DQA*501+ untreated children with juvenile dermatomyositis very early in their disease course: evidence of a TCRb8 motif and increase CD56+ NK cells. Arthritis Rheum 1998, 41(Suppl 9):203.
68. Ottaviani C, Nasorri F, Bedini C, de Pità O, Girolomoni G, Cavani A. CD56brightCD16(-) NK cells accumulate in psoriatic skin in response to CXCL10 and CCL5 and exacerbate skin inflammation. Eur J Immunol 2006, 36:118-128. 10.1002/eji.200535243, 16323244.
69. Dalbeth N, Callan MFC. A subset of natural killer cell s is greatly expanded within inflamed joints. Arthritis Rheum 2002, 46:1763-1772. 10.1002/art.10410, 12124859.
70. Pridgeon C, Lennon GP, Pazmany L, Thompson RN, Christm as SE, Moots RJ. Natural killer cells in the synovial fluid of rheumatoid arthritis patients exhibit a CD56bright,CD94bright,CD158negative phenotype. Rheumatology (Oxford) 2003, 42:870-878.
71. Yabuhara A, Yang FC, Nakazawa T, Iwasaki Y, Mori T, Koike K, Kawai H, Komiyama A. A killing defect of natural killer cells as an underlying immunologic abnormality in childhood systemic lupus erythematosus. J Rheumatol 1996, 23:171-177.
72. Rodacki M, Svoren B, Butty V, Besse W, Laffel L, Benoist C, Mathis D. Altered natural killer cells in type 1 diabetic patients. Diabetes 2007, 56:177-185. 10.2337/db06-0493, 17192480.
73. Willcox A, Richardson SJ, Bone AJ, Foulis AK, Morgan N G. Analysis of islet inflammation in human type 1 diabetes. Clin Exp Immunol 2009, 155:173-181. 10.1111/j.1365-2249.2008.03860.x, 2675247, 19128359.
74. Gur C, Porgador A, Elboim M, Gazit R, Mizrahi S, Stern-Ginossar N, Achdout H, Ghadially H, Dor Y, Nir T, Doviner V, Hershkovitz O, Mendelson M, Naparstek Y, Mandelboim O. The activating receptor NKp46 is essential for the development of type 1 diabetes. Nat Immunol 2010, 11:121-128. 10.1038/ni.1834, 20023661.
75. Poirot L, Benoist C, Mathis D. Natural killer cells distinguish innocuous and destructive forms of pancreatic islet autoimmunity. Proc Natl Acad Sci USA 2004, 101:8102-8107. 10.1073/pnas.0402065101, 419564, 15141080.
76. Brauner H, Elemans M, Lemos S, Broberger C, Holmberg D, Flodstrom-Tullberg M, Karre K, Hoglund P. Distinct phenotype and function of NK cells in the pancreas of nonobese diabetic mice. J Immunol 2010, 184:2272-2280. 10.4049/jimmunol.0804358, 20130214.
77. Kastrukoff LF, Morgan NG, Zecchini D, White R, Petkau AJ, Satoh J, Paty DW. A role for natural killer cells in the immunopathogenesis of multiple sclerosis. J Neuroimmunol 1998, 86:123-133. 10.1016/S0165-5728(98)00014-9, 9663557.
78. Gonzalez-Amaro R, Alcocer-Varela J, Alarcón-Segovia D. Natural killer cell activity in dermatomyositis-polymyositis. J Rheumatol 1987, 14:307-310.
79. Lima M, Almeida J, Montero AG, Teixeira Mdos A, Queiros ML, Santos AH, Balanzategui A, Estevinho A, Alguero Mdel C, Barcena P, Fonseca S, Amorim ML, Cabeda JM, Pinho L, Gonzalez M, San Miguel J, Justiça B, Orfão A. Clinicobiological, immunophenotypic, and molecular characteristics of monoclonal CD56-/+dim chronic natural killer cell large granular lymphocytosis. Am J Pathol 2004, 165:1117-1127. 10.1016/S0002-9440(10)63373-1, 1618630, 15466379.
80. Orange JS, Chehimi J, Ghavimi D, Campbell D, Sullivan KE. Decreased natural killer (NK) cell function in chronic NK cell lymphocytosis associated with decreased surface expression of CD11b. Clin Immunol 2001, 99:53-64. 10.1006/clim.2001.5002, 11286541.
81. French AR, Kim S, Fehniger TA, Pratt JR, Yang L, Song YJ, Caligiuri MA, Yokoyama WM. Chronic lymphocytosis of functionally immature natural killer cells. J Allergy Clin Immunol 2007, 120:924-931. 10.1016/j.jaci.2007.05.022, 17604094.
82. Lamy T, Loughran TP. Clinical features of large granular lymphocyte leukemia. Semin Hematol 2003, 40:185-195. 10.1016/S0037-1963(03)00133-1, 12876667.
83. Tefferi A, Li CY, Witzig TE, Dhodapkar MV, Okuno SH, Phyliky RL. Chronic natural killer cell lymphocytosis: a descriptive clinical study. Blood 1994, 84:2721-2725.
84. Rabbani GR, Phyliky RL, Tefferi A. A long-term study of patients with chronic natural killer cell lymphocytosis. Br J Haematol 1999, 106:960-966. 10.1046/j.1365-2141.1999.01624.x, 10519998.
85. Bashirova AA, Martin MP, McVicar DW, Carrington M. The killer immunoglobulin-like receptor gene cluster: tuning the genome for defense. Annu Rev Genomics Hum Genet 2006, 7:277-300. 10.1146/annurev.genom.7.080505.115726, 16824023.
86. Kulkarni S, Martin MP, Carrington M. The Yin and Yang of HLA and KIR in human disease. Semin Immunol 2008, 20:343-352. 10.1016/j.smim.2008.06.003, 3501819, 18635379.
87. Martin MP, Gao X, Lee J-H, Nelson GW, Detels R, Goedert J J, Buchbinder S, Hoots K, Vlahov D, Trowsdale J, Wilson M, O'Brien SJ, Carrington M. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat Genet 2002, 31:429-434.
88. Alter G, Martin MP, Teigen N, Carr WH, Suscovich TJ, Schneidewind A, Streeck H, Waring M, Meier A, Brander C, Lifson JD, Allen TM, Carrington M, Altfeld M. Differential natural killer cell-mediated inhibition of HIV-1 replication based on distinct KIR/HLA subtypes. J Exp Med 2007, 204:3027-3036. 10.1084/jem.20070695, 2118524, 18025129.
89. Yen JH, Moore BE, Nakajima T, Scholl D, Schaid DJ, Weyand CM, Goronzy JJ. Major histocompatibility complex class i-recognizing receptors are disease risk genes in rheumatoid arthritis. J Exp Med 2001, 193:1159-1168. 10.1084/jem.193.10.1159, 2193323, 11369787.
90. Martin MP, Nelson G, Lee J-H, Pellett F, Gao X, Wade J, Wilson MJ, Trowsdale J, Gladman D, Carrington M. Cutting edge: susceptibility to psoriatic arthritis: influence of activating killer Ig-like receptor genes in the absence of specific HLA-C alleles. J Immunol 2002, 169:2818-2822.
91. van der Slik AR, Koeleman BPC, Verduijn W, Bruining GJ, Roep BO, Giphart MJ. KIR in type 1 diabetes: disparate distribution of activating and inhibitory natural killer cell receptors in patients versus HLA-matched control subjects. Diabetes 2003, 52:2639-2642. 10.2337/diabetes.52.10.2639, 14514651.
92. Takeno M, Shimoyama Y, Kashiwakura J-I, Nagafuchi H, Sakane T, Suzuki N. Abnormal killer inhibitory receptor expression on natural killer cells in patients with Behçet's disease. Rheumatol Int 2004, 24:212-216.
93. Nelson GW, Martin MP, Gladman D, Wade J, Trowsdale J, Carrington M. Cutting edge: heterozygote advantage in autoimmune disease: hierarchy of protection/susceptibility conferred by HLA and killer Ig-like receptor combinations in psoriatic arthritis. J Immunol 2004, 173:4273-4276.
94. Chan AT, Kollnberger SD, Wedderburn LR, Bowness P. Expansion and enhanced survival of natural killer cells expressing the killer immunoglobulin-like receptor KIR3DL2 in spondylarthritis. Arthritis Rheum 2005, 52:3586-3595. 10.1002/art.21395, 16255049.
95. Fusco C, Guerini FR, Nocera G, Ventrella G, Caputo D, Valentino MA, Agliardi C, Gallotti J, Morra VB, Florio C, Clerici M, Lombardi ML. KIRs and their HLA ligands in remitting-relapsing multiple sclerosis. J Neuroimmunol 2010, 229:232-237. 10.1016/j.jneuroim.2010.08.004, 20826009.
96. Pellett F, Siannis F, Vukin I, Lee P, Urowitz MB, Gladman DD. KIRs and autoimmune disease: studies in systemic lupus erythematosus and scleroderma. Tissue Antigens 2007, 69(Suppl 1):106-108.
97. Momot T, Koch S, Hunzelmann N, Krieg T, Ulbricht K, Schmidt RE, Witte T. Association of killer cell immunoglobulin-like receptors with scleroderma. Arthritis Rheum 2004, 50:1561-1565. 10.1002/art.20216, 15146426.
98. Morandi B, Bramanti P, Bonaccorsi I, Montalto E, Oliveri D, Pezzino G, Navarra M, Ferlazzo G. Role of natural killer cells in the pathogenesis and progression of multiple sclerosis. Pharmacol Res 2008, 57:1-5. 10.1016/j.phrs.2007.11.003, 18182304.
99. Gandhi R, Laroni A, Weiner HL. Role of the innate immune system in the pathogenesis of multiple sclerosis. J Neuroimmunol 2010, 221:7-14. 10.1016/j.jneuroim.2009.10.015, 2854189, 19931190.
100. Jiang W, Chai NR, Maric D, Bielekova B. Unexpected role for granzyme K in CD56bright NK cell-mediated immunoregulation of multiple sclerosis. J Immunol 2011, 187:781-790. 10.4049/jimmunol.1100789, 3131478, 21666061.
101. Morse RH, Séguin R, McCrea EL, Antel JP. NK cell-mediated lysis of autologous human oligodendrocytes. J Neuroimmunol 2001, 116:107-115. 10.1016/S0165-5728(01)00289-2, 11311336.
102. Saikali P, Antel JP, Newcombe J, Chen Z, Freedman M, Blain M, Cayrol R, Prat A, Hall JA, Arbour N. NKG2D-mediated cytotoxicity toward oligodendrocytes suggests a mechanism for tissue injury in multiple sclerosis. J Neurosci 2007, 27:1220-1228. 10.1523/JNEUROSCI.4402-06.2007, 17267578.
103. Zhang BN, Yamamura T, Kondo T, Fujiwara M, Tabira T. Regulation of experimental autoimmune encephalomyelitis by natural killer (NK) cells. J Exp Med 1997, 186:1677-1687. 10.1084/jem.186.10.1677, 2199138, 9362528.
104. Matsumoto Y, Kohyama K, Aikawa Y, Shin T, Kawazoe Y, Suzuki Y, Tanuma N. Role of natural killer cells and TCR gamma delta T cells in acute autoimmune encephalomyelitis. Eur J Immunol 1998, 28:1681-1688. 10.1002/(SICI)1521-4141(199805)28:05<1681::AID-IMMU1681>3.0.CO;2-T, 9603475.
105. Xu W, Fazekas G, Hara H, Tabira T. Mechanism of natural killer (NK) cell regulatory role in experimental autoimmune encephalomyelitis. J Neuroimmunol 2005, 163:24-30. 10.1016/j.jneuroim.2005.02.011, 15885305.
106. Huang D, Shi F-D, Jung S, Pien GC, Wang J, Salazar-Mather TP, He TT, Weaver JT, Ljunggren HG, Biron CA, Littman DR, Ransohoff RM. The neuronal chemokine CX3CL1/fractalkine selectively recruits NK cells that modify experimental autoimmune encephalomyelitis within the central nervous system. FASEB J 2006, 20:896-905. 10.1096/fj.05-5465com, 16675847.
107. Winkler-Pickett R, Young HA, Cherry JM, Diehl J, Wine J, Back T, Bere WE, Mason AT, Ortaldo JR. In vivo regulation of experimental autoimmune encephalomyelitis by NK cells: alteration of primary adaptive responses. J Immunol 2008, 180:4495-4506.
108. Shi FD, Takeda K, Akira S, Sarvetnick N, Ljunggren HG. IL-18 directs autoreactive T cells and promotes autodestruction in the central nervous system via induction of IFN-gamma by NK cells. J Immunol 2000, 165:3099-3104.
109. Vollmer TL, Liu R, Price M, Rhodes S, La Cava A, Shi F-D. Differential effects of IL-21 during initiation and progression of autoimmunity against neuroantigen. J Immunol 2005, 174:2696-2701.
110. Munschauer FE, Hartrich LA, Stewart CC, Jacobs L. Circulating natural killer cells but not cytotoxic T lymphocytes are reduced in patients with active relapsing multiple sclerosis and little clinical disability as compared to controls. J Neuroimmunol 1995, 62:177-181. 10.1016/0165-5728(95)00115-9, 7499506.
111. Takahashi K, Miyake S, Kondo T, Terao K, Hatakenaka M, Hashimoto S, Yamamura T. Natural killer type 2 bias in remission of multiple sclerosis. J Clin Invest 2001, 107:R23-R29. 10.1172/JCI11819, 199428, 11238569.
112. Takahashi K, Aranami T, Endoh M, Miyake S, Yamamura T. The regulatory role of natural killer cells in multiple sclerosis. Brain 2004, 127(Pt 9):1917-1927.
113. Hamann I, Dörr J, Glumm R, Chanvillard C, Janssen A, Millward JM, Paul F, Ransohoff RM, Infante-Duarte C. Characterization of natural killer cells in paired CSF and blood samples during neuroinflammation. J Neuroimmunol 2012, 254:165-169.
114. Bielekova B, Catalfamo M, Reichert-Scrivner S, Packer A, Cerna M, Waldmann TA, McFarland H, Henkart PA, Martin R. Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Rα-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci USA 2006, 103:5941-5946. 10.1073/pnas.0601335103, 1458677, 16585503.
115. Bielekova B, Howard T, Packer AN, Richert N, Blevins G, Ohay on J, Waldmann TA, McFarland HF, Martin R. Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis. Arch Neurol 2009, 66:483-489. 10.1001/archneurol.2009.50, 2742781, 19364933.
116. Ahern DJ, Brennan FM. The role of natural killer cells in the pathogenesis of rheumatoid arthritis: major contributors or essential homeostatic modulators?. Immunol Lett 2011, 136:115-121. 10.1016/j.imlet.2010.11.001, 21073898.
117. Conigliaro P, Scrivo R, Valesini G, Perricone R. Emerging role for NK cells in the pathogenesis of inflammatory arthropathies. Autoimmun Rev 2011, 10:577-581. 10.1016/j.autrev.2011.04.017, 21536152.
118. Tak PP, Kummer JA, Hack CE, Daha MR, Smeets TJ, Erkelens GW, Meinders AE, Kluin PM, Breedveld FC. Granzyme-positive cytotoxic cells are specifically increased in early rheumatoid synovial tissue. Arthritis Rheum 1994, 37:1735-1743. 10.1002/art.1780371205, 7986219.
119. de Matos CT, Berg L, Michaëlsson J, Felländer-Tsai L, Kärre K, Söderström K. Activating and inhibitory receptors on synovial fluid natural killer cells of arthritis patients: role of CD94/NKG2A in control of cytokine secretion. Immunology 2007, 122:291-301. 10.1111/j.1365-2567.2007.02638.x, 2266001, 17521371.
120. Zhang AL, Colmenero P, Purath U, Teixeira de Matos C, Hueber W, Klareskog L, Tarner IH, Engleman EG, Söderström K. Natural killer cells trigger differentiation of monocytes into dendritic cells. Blood 2007, 110:2484-2493. 10.1182/blood-2007-02-076364, 1988958, 17626840.
121. Ren J, Feng Z, Lv Z, Chen X, Li J. Natural killer-22 cells in the synovial fluid of patients with rheumatoid arthritis are an innate source of interleukin 22 and tumor necrosis factor-α. J Rheumatol 2011, 38:2112-2118. 10.3899/jrheum.101377, 21765110.
122. Groh V, Bruhl A, El-Gabalawy H, Nelson JL, Spies T. Stimulation of T cell autoreactivity by anomalous expression of NKG2D and its MIC ligands in rheumatoid arthritis. Proc Natl Acad Sci USA 2003, 100:9452-9457. 10.1073/pnas.1632807100, 170939, 12878725.
123. Aramaki T, Ida H, Izumi Y, Fujikawa K, Huang M, Arima K, Tamai M, Kamachi M, Nakamura H, Kawakami A, Origuchi T, Matsuoka N, Eguchi K. A significantly impaired natural killer cell activity due to a low activity on a per-cell basis in rheumatoid arthritis. Mod Rheumatol 2009, 19:245-252. 10.1007/s10165-009-0160-6, 19283441.
124. Wulffraat NM, Rijkers GT, Elst E, Brooimans R, Kuis W. Reduced perforin expression in systemic juvenile idiopathic arthritis is restored by autologous stem-cell transplantation. Rheumatology (Oxford) 2003, 42:375-379.
125. Grom AA, Villanueva J, Lee S, Goldmuntz EA, Passo MH, Filipovich A. Natural killer cell dysfunction in patients with systemic-onset juvenile rheumatoid arthritis and macrophage activation syndrome. J Pediatr 2003, 142:292-296. 10.1067/mpd.2003.110, 12640378.
126. Villanueva J, Lee S, Giannini EH, Graham TB, Passo MH, Filipovich A, Grom AA. Natural killer cell dysfunction is a distinguishing feature of systemic onset juvenile rheumatoid arthritis and macrophage activation syndrome. Arthritis Res Ther 2005, 7:R30-R37. 10.1186/ar1453, 1064882, 15642140.
127. de Jager W, Vastert SJ, Beekman JM, Wulffraat NM, Kuis W, Coffer PJ, Prakken BJ. Defective phosphorylation of interleukin-18 receptor beta causes impaired natural killer cell function in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2009, 60:2782-2793. 10.1002/art.24750, 19714583.
128. Vastert SJ, van Wijk R, D'Urbano LE, de Vooght KMK, de Jager W, Ravelli A, Magni-Manzoni S, Insalaco A, Cortis E, van Solinge WW, Prakken BJ, Wulffraat NM, de Benedetti F, Kuis W. Mutations in the perforin gene can be linked to macrophage activation syndrome in patients with systemic onset juvenile idiopathic arthritis. Rheumatology (Oxford) 2010, 49:441-449.
129. Hazen MM, Woodward AL, Hofmann I, Degar BA, Grom A, Filipovich AH, Binstadt BA. Mutations of the hemophagocytic lymphohistiocytosisassociated gene UNC13D in a patient with systemic juvenile idiopathic arthritis. Arthritis Rheum 2008, 58:567-570. 10.1002/art.23199, 18240215.
130. Zhang K, Biroschak J, Glass DN, Thompson SD, Finkel T, Passo MH, Binstadt BA, Filipovich A, Grom AA. Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis is associated with MUNC13-4 polymorphisms. Arthritis Rheum 2008, 58:2892-2896. 10.1002/art.23734, 2779064, 18759271.
131. Lo CKC, Lam QLK, Sun L, Wang S, Ko K-H, Xu H, Wu C-Y, Zheng B-J, Lu L. Natural killer cell degeneration exacerbates experimental arthritis in mice via enhanced interleukin-17 production. Arthritis Rheum 2008, 58:2700-2711. 10.1002/art.23760, 18759269.
132. Nilsson N, Bremell T, Tarkowski A, Carlsten H. Protective role of NK 1.1+ cells in experimental Staphylococcus aureus arthritis. Clin Exp Immunol 1999, 117:63-69. 10.1046/j.1365-2249.1999.00922.x, 1905466, 10403917.
133. Wu H-J, Sawaya H, Binstadt B, Brickelmaier M, Blasius A, Gorelik L, Mahmood U, Weissleder R, Carulli J, Benoist C, Mathis D. Inflammatory arthritis can be reined in by CpG-induced DC-NK cell cross talk. J Exp Med 2007, 204:1911-1922. 10.1084/jem.20070285, 2118664, 17646407.
134. Leavenworth JW, Wang X, Wenander CS, Spee P, Cantor H. Mobilization of natural killer cells inhibits development of collagen-induced arthritis. Proc Natl Acad Sci USA 2011, 108:14584-14589. 10.1073/pnas.1112188108, 3167502, 21873193.
135. Söderström K, Stein E, Colmenero P, Purath U, Müller-Ladner U, de Matos CT, Tarner IH, Robinson WH, Engleman EG. Natural killer cells trigger osteoclastogenesis and bone destruction in arthritis. Proc Natl Acad Sci USA 2010, 107:13028-13033. 10.1073/pnas.1000546107, 2919936, 20615964.
136. Yuan D, Thet S, Zhou XJ, Wakeland EK, Dang T. The role of NK cells in the development of autoantibodies. Autoimmunity 2011, 44:641-651. 10.3109/08916934.2011.587852, 21689027.
137. Takeda K, Dennert G. The development of autoimmunity in C57BL/6 lprmice correlates with the disappearance of natural killer type 1-positive cells: evidence for their suppressive action on bone marrow stem cell proliferation, B cell immunoglobulin secretion, and autoimmune symptoms. J Exp Med 1993, 177:155-164. 10.1084/jem.177.1.155, 2190856, 8418197.
138. Huang Z, Fu B, Zheng SG, Li X, Sun R, Tian Z, Wei H. Involvement of CD2 26+ NK cells in immunopathogenesis of systemic lupus erythematosus. J Immunol 2011, 186:3421-3431. 10.4049/jimmunol.1000569, 3097030, 21296979.
139. Schleinitz N, Chiche L, Guia S, Bouvier G, Vernier J, Morice A, Houssaint E, Harlé J-R, Kaplanski G, Montero-Julian FA, Vély F. Pattern of DAP12 expression in leukocytes from both healthy and systemic lupus erythematosus patients. PLoS ONE 2009, 4:e6264. 10.1371/journal.pone.0006264, 2707004, 19606219.
140. Hervier B, Beziat V, Haroche J, Mathian A, Lebon P, Ghillani-Dalbin P, Musset L, Debré P, Amoura Z, Vieillard V. Phenotype and function of natural killer cells in systemic lupus erythematosus: excess interferon-γ production in patients with active disease. Arthritis Rheum 2011, 63:1698-1706. 10.1002/art.30313, 21370226.
141. Puxeddu I, Bongiorni F, Chimenti D, Bombardieri S, Moretta A, Bottino C, Migliorini P. Cell surface expression of activating receptors and coreceptors on peripheral blood NK cells in systemic autoimmune diseases. Scand J Rheumatol 2012, 41:298-304. 10.3109/03009742.2011.648657, 22632143.
142. Erkeller-Yuksel FM, Lydyard PM, Isenberg DA. Lack of NK cells in lupus patients with renal involvement. Lupus 1997, 6:708-712. 10.1177/096120339700600905, 9412985.
143. Riccieri V, Spadaro A, Parisi G, Taccari E, Moretti T, Bernardini G, Favaroni M, Strom R. Down-regulation of natural killer cells and of gamma/delta T cells in systemic lupus erythematosus. Does it correlate to autoimmunity and to laboratory indices of disease activity?. Lupus 2000, 9:333-337. 10.1191/096120300678828460, 10878724.
144. Schepis D, Gunnarsson I, Eloranta M-L, Lampa J, Jacobson SH, Kärre K, Berg L. Increased proportion of CD56bright natural killer cells in active and inactive systemic lupus erythematosus. Immunology 2009, 126:140-146. 10.1111/j.1365-2567.2008.02887.x, 2632704, 18564343.
145. Green MRJ, Kennell ASM, Larche MJ, Seifert MH, Isenberg DA, Salaman MR. Natural killer cell activity in families of patients with systemic lupus erythematosus: demonstration of a killing defect in patients. Clin Exp Immunol 2005, 141:165-173. 10.1111/j.1365-2249.2005.02822.x, 1809425, 15958083.